Exagen Featured in Nine Scientific Presentations at 2019 ACR/ARHP Annual Meeting in Atlanta
October 28 2019 - 8:15AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced they will be presenting new scientific data at the
American College of Rheumatology’s (ACR/ARHP) Annual Meeting being
held November 9-12, 2019 in Atlanta, GA.
“We are very pleased to have nine abstracts
accepted including 5 posters and 4 podium presentations at the
ACR/ARHP Annual Conference,” shared Thierry Dervieux, Chief
Scientific Officer at Exagen. “Not only is this the greatest number
of abstracts we have ever presented, but it also reflects the most
diverse representation of the laboratory science we are
investigating at Exagen. The topics we will be reporting on include
clinical utility and clinical validity of the AVISE Lupus test,
novel biomarkers in rheumatoid arthritis and lupus, and therapeutic
optimization of some of the most widely used drugs in
rheumatology.”
A list of accepted abstracts along with links is
included below.
Nov 10th
Poster Presentation I Presented by Rosalind
Ramsey-Goldman, MD I Abstract: 669 Title: Complement
Activation in Probable Systemic Lupus Erythematosus (pSLE) May
Predict Progression to SLE Defined by Fulfillment of ACR
Classification Criteria Session Title: SLE -
Clinical Poster II: Comorbidities
Podium Presentation | Presented by Daniel J. Wallace, MD
| Abstract: 942 Title: A Randomized
Prospective Trial to Assess the Clinical Utility of Multianalyte
Assay with Complement Activation Products in Diagnosing
Systemic Lupus Erythematosus Session Title: SLE–Clinical III:
Clinical Trials II
Nov 11th
Poster Presentation I
Presented by Michelle Petri, MD I Abstract: 1602
Title: Persistency in Platelet C4d and Thrombosis Risk Score
Associated with Thrombosis in Systemic Lupus Erythematosus Session
Title: SLE - Clinical Poster I: Epidemiology & Pathology
Poster Presentation I Presented by Yevgeniya Gartshteyn,
MD I Abstract: 1617 Title: Platelet Bound Complement Split
Product (PC4d) May Be a Marker of Platelet Activation and
Cardiovascular Events in Systemic Lupus Erythematosus Session
Title: SLE - Clinical Poster II: Comorbidities
Podium Presentation I Presented by Michelle Petri, MD I
Abstract: 1825 Title: Comparison of the Thrombosis Risk
Score with Triple Positivity in SLE Thrombosis Session Title:
3S082: SLE - Clinical II: Flares & Morbidity of SLE
Podium Presentation I Presented by Thierry Dervieux, PhD
I Abstract: 1886 Title: Antibody Systems Targeting
Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase
Autoantigens Distinguish Rheumatoid Arthritis in Combination with
Rheumatoid Factors Session Title: 4M116: RA - Diagnosis,
Manifestations, & Outcomes III: Diagnosis & Prognosis
Nov 12th
Poster Presentation I Presented by Thierry Dervieux, PhD
I Abstract: 2401 Title: Enhanced Methotrexate
Polyglutamation in Japanese as Compared to Caucasian Rheumatoid
Arthritis Patients Starting Methotrexate Session Title: RA -
Treatment Poster III: Safety and Outcomes
Poster Presentation I Presented by Thierry Dervieux, PhD
I Abstract: 2536 Title: Distribution and Predictors of
Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology
Practices in the United States Session Title: SLE - Clinical Poster
III: Treatment
Nov 13th
Podium Presentation I Presented by Solani Narain, MD,
MPH I Abstract: 2887 Title: Cell-bound Complement
Activation Products in Combination with Low Complement C3 or C4
Have Superior Diagnostic Performance in Systemic Lupus
Erythematosus Session Title: ACR Abstract: SLE–Clinical II:
Epidemiology, Diagnosis, & Outcome
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
Forward-Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding the scientific
abstracts accepted for presentation at ACR/ARHP Annual Conference
and the potential to lead to increased adoption of any AVISE test.
The inclusion of forward-looking statements should not be regarded
as a representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: Exagen’s
commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; if third-party payers do not
provide coverage and adequate reimbursement for Exagen’s testing
products, or they breach, rescind or modify their contracts or
reimbursement policies or delay payments for its testing products
or promoted therapeutics, or if Exagen or its partners are unable
to successfully negotiate payer contracts, Exagen’s commercial
success could be compromised; and other risks described in the
Company’s prior press releases and in the Company’s filings with
the Securities and Exchange Commission, including under the heading
"Risk Factors" in the Company’s Registration Statement on Form S-1
and any subsequent filings with the SEC. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and we undertake no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, which
is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
CONTACTS:
Westwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838 Exagen Inc. Brian
McEvillybmcevilly@exagen.com760.560.1506
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Oct 2023 to Oct 2024